Gut Disorders Treatment Market Size, Share, and Growth Forecast 2026 - 2033

The global gut disorders treatment market size is likely to be valued at US$44.3 billion in 2026 and is estimated to reach US$51.5 billion by 2033, growing at a CAGR of 2.2% during the forecast period from 2026 to 2033, driven by the continuing need to manage gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), constipation, diarrhea, and other chronic gastrointestinal conditions. Rising diagnoses, long treatment periods, and the introduction of targeted biologics are also widening treatment options.

Driver - Rising Burden of Chronic Gastrointestinal Disorders to Boost Treatment Demand

The continuing prevalence of chronic digestive disorders is creating a steady requirement for prescription and over-the-counter treatment. GERD, IBS, constipation, diarrhea, Crohn’s disease, and ulcerative colitis often require repeated consultations, medication changes, or long-term maintenance therapy rather than a single treatment course. This creates recurring demand across acid suppressants, laxatives, antidiarrheals, anti-inflammatory medicines, biologics, and newer targeted therapies.

The treatment landscape is also becoming more structured as patients receive earlier evaluation and more disease-specific therapy. For IBD, treatment increasingly focuses on achieving and maintaining remission, reducing inflammation, and limiting complications rather than managing symptoms alone. For functional disorders such as IBS, treatment remains more symptom-directed, with options selected according to constipation, diarrhea, abdominal pain, or bloating. This wide range of treatment needs gives suppliers multiple routes to address the gut disorders treatment market.

Expansion of Targeted Therapies to Strengthen Advanced Treatment Adoption

The development of targeted medicines is changing the treatment mix for inflammatory gastrointestinal diseases. Biologics and small-molecule therapies can act on specific inflammatory pathways and are increasingly used when conventional treatment does not provide adequate control. This is particularly important in Crohn’s disease and ulcerative colitis, where patients may cycle through several therapies over the course of the disease.

Recent approvals exhibit this shift. In March 2025, the FDA approved TREMFYA (guselkumab) for adults with moderately to severely active Crohn’s disease, expanding its use after approval for ulcerative colitis. In January 2025, the FDA approved Omvoh (mirikizumab) for adults with moderately to severely active Crohn’s disease, giving the therapy a second major IBD indication. Such label expansions increase the number of treatment choices available to physicians and support continued investment in gastrointestinal drug development.

Restraint- High Treatment Costs and Complex Administration May Limit Access

Advanced gastrointestinal treatments can face affordability and administration barriers, particularly biologics that require specialist prescribing, injections, infusions, monitoring, or prior authorization. These requirements can make treatment less convenient than oral medicines and can restrict access in healthcare systems where reimbursement coverage is limited. Even when a therapy is clinically appropriate, the total cost of treatment and the infrastructure needed to administer it can influence patient and provider choices.

Complexity is also relevant to adherence. Chronic gastrointestinal diseases often fluctuate between periods of improvement and relapse, and patients may stop or change therapy when symptoms improve. Injectable and infusion-based treatments can reduce daily pill burden for some patients, but they also introduce appointment and administration requirements. The availability of biosimilars and additional oral options is therefore becoming important for improving treatment flexibility and potentially reducing access barriers.

Opportunity - Development of Oral and Gut-Targeted Therapies to Improve Convenience

The growing interest in oral and locally acting therapies is creating opportunities for developers to address convenience without abandoning disease-specific treatment. Oral small molecules can offer an alternative to injections or infusions, while gut-targeted approaches aim to deliver activity closer to the site of disease. These approaches are especially relevant in IBD, where patients may need treatment for many years and value flexibility in administration.

Pipeline activity supports this opportunity. In June 2026, Palisade Bio received FDA clearance for the investigational drug PALI-2108 and planned a global Phase 2 study in moderately to severely active ulcerative colitis. The company describes the therapy as an oral PDE4 inhibitor prodrug designed for targeted local bioactivation. In February 2026, Sanofi and Teva reported 44-week maintenance data for investigational duvakitug in ulcerative colitis and Crohn’s disease, with Phase 3 programs ongoing. These developments show continued movement toward differentiated mechanisms and more convenient treatment formats.

Pediatric Gastrointestinal Care to Open New Treatment Opportunities

Pediatric care is another area where treatment development can expand the addressable market. Children with IBD may require long-term disease control during periods of growth and development, making effective and age-appropriate therapies particularly important. Regulatory expansion into younger age groups can therefore create new treatment pathways while also encouraging companies to generate pediatric safety and efficacy data.

Recent regulatory activity illustrates the opportunity. In April 2026, the FDA approved Stelara for pediatric Crohn’s disease in patients aged 2 years and older and later expanded the indication to pediatric ulcerative colitis. In November 2025, FDA also approved Linzess (linaclotide) for children aged 7 years and older with IBS with constipation, representing the first prescription treatment approved for that pediatric IBS-C population. These developments broaden the treatment landscape beyond adult gastrointestinal care.

Drug Class Insights

Biologics and biosimilars are anticipated to dominate the drug class segment, with a share of around 44.7% in 2025, as they are widely used in moderate-to-severe Crohn’s disease and ulcerative colitis. Their role has expanded as treatment has moved toward targeted control of inflammation and maintenance of remission. The segment also benefits from continued innovation around IL-23, TNF, integrin, and other immune pathways, while biosimilar availability is creating additional options as established biologic products face competition.

Laxatives, acid suppressants, antidiarrheals, and other conventional therapies continue to account for substantial demand as they address high-volume gastrointestinal complaints. Their broad use in primary care and retail settings gives them a large patient base, even though their role is generally more symptom-focused than the disease-modifying approach associated with advanced IBD therapies.

Application Insights

Crohn’s disease is anticipated to remain the leading application with a share of around 33.5% in 2025, supported by the need for long-term management and the increasing availability of biologics and targeted medicines. Treatment is increasingly focused on controlling inflammation, maintaining remission, and preventing structural complications. The expansion of therapies into pediatric Crohn’s disease is also widening the treatment population.

Ulcerative colitis is another major application as patients can require repeated induction and maintenance treatment, particularly when disease activity is moderate or severe. GERD and IBS represent large symptom-management categories, supported by broad use of oral medicines. The coexistence of common functional disorders and more complex inflammatory diseases creates a diversified demand base for gastrointestinal treatment products.

North America Gut Disorders Treatment Market Trends

North America is predicted to dominate globally with a share of approximately 37.9% in 2025, supported by advanced healthcare infrastructure, high diagnosis rates, specialist gastroenterology services, and rapid adoption of innovative therapies. The region has also become an important market for biologics and targeted medicines used in IBD. Reimbursement, specialty pharmacy networks, and strong clinical research activity support the availability of newer treatment options.

U.S. Gut Disorders Treatment Market Trends

The U.S. represents the largest national market within North America owing to its large treated patient population, established specialty-care network, and rapid uptake of newly approved gastrointestinal therapies. Recent FDA activity has expanded treatment options across both adult and pediatric populations. Approvals for pediatric IBS-C and pediatric IBD are also increasing the range of age groups eligible for prescription treatment.

Asia Pacific Gut Disorders Treatment Market Trends

Asia Pacific is expected to register the fastest growth during the forecast period as healthcare access expands, diagnostic capabilities improve, and gastrointestinal disorders receive greater clinical attention. Japan, China, India, South Korea, and Australia have established pharmaceutical and hospital systems that can support broader treatment adoption. Rising urbanization and changes in diet are also increasing the need for both symptom management and chronic disease care.

China Gut Disorders Treatment Market Trends

China is becoming an important gastrointestinal treatment market as its healthcare system expands access to specialty medicines and local pharmaceutical development. Regulatory approvals for innovative IBD therapies are increasing treatment choices. In February 2026, Eli Lilly received Chinese regulatory approval for mirikizumab for Crohn’s disease and ulcerative colitis, extending an innovative digestive-immunity treatment into one of the region’s largest pharmaceutical markets.

India Gut Disorders Treatment Market Trends

India is expected to see rising demand for gut disorder treatments as diagnosis improves and private and public healthcare networks expand. The market has a large base of patients seeking treatment for reflux, constipation, diarrhea, IBS, and other gastrointestinal symptoms, while tertiary hospitals are also increasing access to advanced IBD management. Growth in specialist care and greater awareness of persistent digestive symptoms can support earlier consultation and treatment.

Europe Gut Disorders Treatment Market Trends

Europe is supported by mature healthcare systems, established gastroenterology networks, and broad access to prescription medicines. The region has a strong base for biologic treatment of IBD and is also seeing increased attention to biosimilars and treatment optimization. Differences in reimbursement and national health technology assessment processes, however, can affect the speed at which newer therapies reach patients.

Germany Gut Disorders Treatment Market Trends

Germany remains an important European market owing to its large healthcare system, specialist treatment capacity, and established pharmaceutical infrastructure. Gastroenterology centers provide access to advanced biologic and targeted therapies, while pharmacies remain an important channel for conventional gastrointestinal medicines. Continued attention to treatment costs and reimbursement will influence the adoption of newer products.

U.K. Gut Disorders Treatment Market Trends

The U.K. market benefits from a national healthcare system with established pathways for diagnosing and managing gastrointestinal diseases. Specialist IBD services and national treatment guidance support structured care, while new therapies are assessed for clinical and economic value before wider adoption. Pediatric treatment expansion and greater use of targeted medicines are expected to remain important areas of development.

The global gut disorders treatment market is moderately consolidated in advanced therapies but remains diverse across the broad treatment spectrum. Large pharmaceutical companies, specialty biopharma firms, generic-drug manufacturers, and emerging biotechnology companies compete through new mechanisms, expanded indications, oral formulations, biologics, biosimilars, and improved treatment convenience. Competition is particularly active in IBD, where companies are developing therapies against different inflammatory pathways and seeking differentiated efficacy, safety, and administration profiles.

Key Industry Developments:

• In June 2026, Takeda announced that the FDA accepted its supplemental Biologics License Application for intravenous ENTYVIO (vedolizumab) in pediatric patients aged 2 years and older with moderately to severely active ulcerative colitis or Crohn’s disease. The application is intended to expand the use of the gut-selective biologic into a pediatric population with continuing treatment needs.
• In May 2026, AbbVie presented 18 abstracts at Digestive Disease Week covering Crohn’s disease and ulcerative colitis, including long-term clinical-trial and real-world evidence for SKYRIZI (risankizumab) and RINVOQ (upadacitinib). The company reported that the data further evaluated the therapies’ efficacy, safety, and durability in inflammatory bowel disease, supporting continued expansion of evidence around targeted treatments for chronic gut disorders.
• In April 2026, AbbVie submitted an application to the FDA seeking approval of subcutaneous induction with SKYRIZI (risankizumab-rzaa) for adults with moderately to severely active Crohn’s disease. The application was supported by results from the phase 3 AFFIRM study and, if approved, would provide an additional subcutaneous induction option for patients already eligible for intravenous induction with risankizumab.